Alan W. Partin
Medical Practice in Baltimore, MD
License number
DC MD041892
Issued Date
Oct 10, 2013
Expiration Date
Dec 31, 2018
Category
MEDICINE
Type
MEDICINE AND SURGERY
Address
Address
Johns Hopkins University Som, Baltimore, MD 21287
Personal information
See more information about Alan W. Partin at radaris.comName
Address
Phone
14200 Carroll Ridge Ct, Baldwin, MD 21013
6400 Catalpa Rd, Fork, MD 21051
6400 Catalpa Rd, Fork, MD 21051
7 Hedgeford Ct, Nottingham, MD 21236
Organization information
See more information about Alan W. Partin at bizstanding.comAlan W Partin MD
600 N Wolfe St, Baltimore, MD 21287
Industry:
Medical Doctor's Office
Osteopathys:
Meghan Pratts (Medical Doctor),Alan Partin (Owner),Aarti Mathur (Medical Doctor),...
Professional information
Alan Partin, Baltimore MD
Work:
The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287 Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD 21224
600 N Wolfe St, Baltimore, MD 21287 Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287 Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD 21224
Method Of Enriching Rare Cells
US Patent:
5962237, Oct 5, 1999
Filed:
Apr 2, 1997
Appl. No.:
8/832468
Inventors:
Paul O. P. Ts'o - Ellicott City MD
Stephen A. Lesko - Baltimore MD
William G. Nelson - Towson MD
Alan W. Partin - Baltimore MD
Stephen A. Lesko - Baltimore MD
William G. Nelson - Towson MD
Alan W. Partin - Baltimore MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353, G01N 930, B01D 3315
US Classification:
435 723
Abstract:
A method for enriching cancer cells such as prostate cancer cells in a bodily fluid sample is disclosed comprising (a) obtaining the sample comprising cancer cells and non-rare cells; (b) subjecting the sample to multiple density gradient separation comprising a first density gradient and a second density gradient, wherein the second density gradient is greater than the first density gradient, and producing a first fluid comprising an increased concentration of cancer cells of a first density, and a second fluid comprising an increased concentration of cancer cells of a second density, wherein the second density is greater than the first density; wherein subjecting the sample to multiple density gradient separation includes producing a plasma layer, a first interface layer, a first gradient layer, a second interface layer, a second gradient layer, and a cell pellet; wherein producing the first fluid includes combining the first interface layer and the first gradient layer and forming a first suspension; and wherein producing the second fluid includes combining the second interface layer and the second gradient layer and forming a second suspension; (c) subjecting said second fluid comprising the second suspension to a binding agent that binds non-rare cells; and (d) removing the bound non-rare cells from the second fluid to provide a second fluid enriched with the greater density cancer cells.
Nuclear Matrix Proteins
US Patent:
6030793, Feb 29, 2000
Filed:
Feb 23, 1999
Appl. No.:
9/256428
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford CT
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford CT
Assignee:
The John Hopkins University School of Medicine
International Classification:
C07K 1618, C12Q 100, G01N 3353
US Classification:
435 71
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
Nuclear Matrix Proteins
US Patent:
2002016, Nov 14, 2002
Filed:
Oct 20, 1998
Appl. No.:
09/175230
Inventors:
DONALD S. COFFEY - LUTHERVILLE MD, US
ALAN W. PARTIN - BALTIMORE MD, US
ROBERT H. GETZENBERG - PITTSBURGH PA, US
ALAN W. PARTIN - BALTIMORE MD, US
ROBERT H. GETZENBERG - PITTSBURGH PA, US
International Classification:
G01N033/574
US Classification:
435/007230
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
Nuclear Matrix Proteins
US Patent:
2003014, Jul 31, 2003
Filed:
Jan 29, 2003
Appl. No.:
10/354480
Inventors:
Donald Coffey - Lutherville MD, US
Alan Partin - Baltimore MD, US
Robert Getzenberg - Pittsburgh PA, US
Alan Partin - Baltimore MD, US
Robert Getzenberg - Pittsburgh PA, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
Method For Detecting Prostate Cancer Using A Reagent Which Binds Prostate Cancer-1 Protein
US Patent:
5824490, Oct 20, 1998
Filed:
May 31, 1995
Appl. No.:
8/455558
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Pittsburgh PA
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Pittsburgh PA
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353
US Classification:
435 723
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. Also provided is an in vitro method for detecting prostate cancer in a sample employing a reagent that reacts with the NMP designated PC-1 (prostate cancer-1).
Method Of Enriching Rare Cells
US Patent:
2003011, Jun 26, 2003
Filed:
Oct 25, 2002
Appl. No.:
10/281043
Inventors:
Paul Ts'o - Ellicot City MD, US
Stephen Lesko - Baltimore MD, US
William Nelson - Towson MD, US
Alan Partin - Baltimore MD, US
Stephen Lesko - Baltimore MD, US
William Nelson - Towson MD, US
Alan Partin - Baltimore MD, US
Assignee:
John Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N033/567, G01N033/574, C12N005/08
US Classification:
435/007210, 435/007230, 435/366000
Abstract:
The present invention provides for enriching rare cells in a fluid comprising the rare cells and non-rare cells. Examples of rare cells enriched include prostate cancer cells.
Nuclear Matrix Proteins
US Patent:
2006017, Aug 3, 2006
Filed:
Apr 6, 2006
Appl. No.:
11/400698
Inventors:
Donald Coffey - Lutherville MD, US
Alan Partin - Baltimore MD, US
Robert Getzenberg - Pittsburgh PA, US
Alan Partin - Baltimore MD, US
Robert Getzenberg - Pittsburgh PA, US
International Classification:
G01N 33/574
US Classification:
435007230
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
Nuclear Matrix Proteins
US Patent:
5849509, Dec 15, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/488036
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
G01N 33574, G01N 3353
US Classification:
435 723
Abstract:
Nuclear matrix proteins (NMP) which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.
Antibodies To Nuclear Matrix Proteins
US Patent:
5874539, Feb 23, 1999
Filed:
Jun 2, 1995
Appl. No.:
8/459023
Inventors:
Donald S. Coffey - Lutherville MD
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford CT
Alan W. Partin - Baltimore MD
Robert H. Getzenberg - Branford CT
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C07K 1618
US Classification:
5303871
Abstract:
Antibodies directed to nuclear matrix proteins (NMP) are provided. Such antibodies are useful markers in diagnosing and monitoring the stage of malignancy of a cell.